SCHEMBL7761691

SCHEMBL7761691

Cc1ccc(C(N)=O)c(N)c1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.42
SIRT3 Q9NTG7 1/20 0.42
PKMYT1 Q99640 1/20 0.39
NNMT P40261 2/20 0.39
POLB P06746 1/20 0.38
MAPT P10636 3/20 0.38
ALDH1A1 P00352 2/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
MAPK1 P28482 1/20 0.38
MKNK1 Q9BUB5 1/20 0.37
MKNK2 Q9HBH9 1/20 0.37
BCAT2 O15382 1/20 0.36
JAK2 O60674 1/20 0.36
BTK Q06187 1/20 0.36
KDM4E B2RXH2 2/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CLCN2 P51788 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3048462 0.84 POLB (0.39) TDP1POLBMAPTKMT2AMEN1
SCHEMBL1149742 0.83 KDM4E (0.48) TDP1POLBMAPTALDH1A1KMT2A
SCHEMBL9890969 0.83 POLB (0.38) TDP1POLBMAPTALDH1A1MAPK1
SCHEMBL27614341 0.83 POLB (0.48) TDP1SIRT3PKMYT1NNMTPOLB
SCHEMBL354227 0.82 SIRT3 (0.45) TDP1SIRT3PKMYT1NNMTMAPT
SCHEMBL11457957 0.81 POLB (0.37) TDP1PKMYT1POLBMAPTALDH1A1
SCHEMBL10800974 0.81 KDM4E (0.47) TDP1POLBMAPTALDH1A1KMT2A
Hydrochloric Acid SCHEMBL27784477 0.81 POLB (0.46) TDP1SIRT3PKMYT1NNMTPOLB
Hydrochloric Acid SCHEMBL1776795 0.80 SIRT3 (0.44) TDP1SIRT3PKMYT1NNMTMAPT
SCHEMBL17818478 0.79 ERN1 (0.44) TDP1SIRT3NNMTMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108191822-A A kind of synthetic method of Rynaxypyr 广东丸美生物技术股份有限公司 2018-06-22 CN claimed
WO-2021111311-A2 NOVEL ADAMANTANE DERIVATIVES AS INHIBITORS OF FOCAL ADHESION KINASE 삼진제약주식회사 2021-06-10 WO disclosed
CN-108191822-A A kind of synthetic method of Rynaxypyr 广东丸美生物技术股份有限公司 2018-06-22 CN disclosed
US-20160168140-A1 HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS SYNERECA PHARMACEUTICALS (US) 2016-06-16 US disclosed
US-8754105-B2 Macrocyclic inhibitors of hepatitis C virus MEDIVIR AB (SE) 2014-06-17 US disclosed
US-20110237621-A1 Macrocyclic Inhibitors of Hepatitis C Virus JANSSEN SCIENCES IRELAND UC (IE) 2011-09-29 US disclosed
US-7989471-B2 Macrocyclic inhibitors of hepatitis C virus TIBOTEC PHARMACEUTICALS LTD. (IE) 2011-08-02 US disclosed
US-20100240698-A1 MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS JANSSEN SCIENCES IRELAND UC (IE) 2010-09-23 US disclosed
CN-1127493-C 1-(N-phenylaminoalkyl)-piperazine derivatives substituted at position 2 of phenyl ring RECORDATI CHEM PHARM (CH) 2003-11-12 CN disclosed
US-6331627-B1 Intermediates of benzoxazinone derivatives and preparation thereof REDDY'S LABORATORIES LTD. (IN) 2001-12-18 US disclosed
CN-1312817-A Dolastatin 15 derivatives BASF AG (DE) 2001-09-12 CN disclosed
EP-1093460-A1 DOLASTATIN 15 DERIVATIVES BASF AKTIENGESELLSCHAFT (DE) 2001-04-25 EP disclosed
CN-1280574-A Heterocyclic compounds, their use in medicine, processes for their preparation and pharmaceutical compositions containing them REDDY CHEMINOR INC (IN) 2001-01-17 CN disclosed
CN-1265654-A 1-(N-phenylaminoalkyl)-piperazine derivatives substituted at position 2 of phenyl ring RECORDATI CHEM PHARM (CH) 2000-09-06 CN disclosed
WO-2000002906-A1 DOLASTATIN 15 DERIVATIVES BASF AKTIENGESELLSCHAFT (DE) 2000-01-20 WO disclosed
EP-0084853-B1 PROCESS FOR THE PREPARATION OF 1,8-NAPHTHOLACTAM COMPOUNDS CIBA-GEIGY AG (CH) 1986-11-12 EP disclosed
US-4515963-A AMIDATIUON OF NAPHTHOLACTONE CIBA GEIGY AG (CH) 1985-05-07 US disclosed
EP-0084853-A1 Process for the preparation of 1,8-naphtholactam compounds CIBA-GEIGY AG (CH) 1983-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160168140-A1 HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS FOS, FOSB, YAP1 TDP1 3875/4885SIRT3 3002/4885PKMYT1 783/4885
US-20110237621-A1 Macrocyclic Inhibitors of Hepatitis C Virus NR4A1, NR4A3, NR4A2 TDP1 4840/4885SIRT3 2272/4885PKMYT1 4384/4885
US-20100240698-A1 MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS CYP2B6, SRD5A1, NR5A2 TDP1 4836/4885SIRT3 1672/4885PKMYT1 4120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.